ChemDiv and Berlex Announce Collaboration

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Safecharge International Group Limited	LSE:SCH	London	Ordinary Share	GG00BYMK4250	ORD USD0.0001

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Safecharge International Group Limited

LSE:SCH

London

Ordinary Share

GG00BYMK4250

ORD USD0.0001

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

435.00

0.00

01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

ChemDiv and Berlex Announce Collaboration

10/03/2006 2:00pm

PR Newswire (US)

Safecharge (LSE:SCH)
Historical Stock Chart

From Jun 2019 to Jun 2024

SAN DIEGO, March 10 /PRNewswire/ -- ChemDiv, Inc., a global chemistry-driven contract research organization, announced today that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR; FSE: SCH). The partners will work on the discovery of potential new lead compounds against several selected GPCR targets. Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies. Financial terms were not disclosed. "We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise. ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc. About ChemDiv, Inc. ChemDiv, Inc. (ChemDiv) is a global chemistry-driven contract research organization focused on the delivery of new scientific innovation, products and services that meet the drug discovery needs of its partners. ChemDiv provides partners with access to Discovery outSource(TM), a full service drug discovery capabilities encompassing: medicinal chemistry; pre-clinical development; synthetic chemistry; diverse and focused screening libraries, as well as global logistics. For additional information, please visit http://www.chemdiv.com/. About Berlex, Inc. Committed to addressing unmet medical needs, Berlex, Inc., a US affiliate of Schering AG, Germany (NYSE:SHR), develops and markets diagnostic imaging agents, treatments in the areas of female health care and dermatology, as well as specialized therapeutics for life-threatening and disabling diseases in the fields of the central nervous and cardiovascular systems, oncology, and gastroenterology. Berlex has business operations in New Jersey, California and Washington. For more information, please visit http://www.berlex.com/. DATASOURCE: ChemDiv, Inc.; Berlex Inc. CONTACT: Rouslan Michtchenko, Director Business Development of ChemDiv, Inc., +1-858-794-4860, or fax, +1-858-794-4931, Web site: http://www.chemdiv.com/ http://www.berlex.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SCH Safecharge International Group Limited